Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IRWD vs AYTU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IRWD Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

IRWD Overall Winner 6-Pillar Tally: IRWD 4 – 2 AYTU Matrix Metrics: IRWD 6 – 4 AYTU

As of Nov 16, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is the stronger overall head-to-head candidate over AYTU BioPharma, Inc. (AYTU) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). IRWD carries a Unified Composite Score of 34.8/100 (SELL) at $4.86 (12.3x Forward P/E, 62.9% operating margin), whereas AYTU carries 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin).

  • Composite vs. Pillar Nuance: While AYTU currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. IRWD 34.8/100 SELL), IRWD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (62.9% vs. -14.4% operating margin) and revenue trajectory (+9.0% vs. +6.4% YoY).
  • Technical & Structure Timing Caution: IRWD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 75.5); meanwhile AYTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IRWD vs AYTU
IRWD NASDAQ Head-to-Head Winner
Ironwood Pharmaceuticals, Inc. - Class A
Pharmaceutical Preparations
$4.86
+0.62% 1D
Market Cap $802.9M
TTM Revenue $400M
Forward P/E 12.3x
Beta / 30D Vol 1.37β · 54% Vol
Unified Composite Score
34.8 / 100 SELL
Tech 50.0 Fund 33.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 76
RSI-14: 75.5 · SMA20: $4.00 · SMA50: $3.98
AYTU NASDAQ
AYTU BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$1.81
+1.69% 1D
Market Cap $19.6M
TTM Revenue $58M
Forward P/E 9.2x
Beta / 30D Vol 0.65β · 35% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 49.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.8%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $1.89 · SMA50: $2.00

6-Pillar Scorecard Institutional Category Breakdown (IRWD 4 – 2 AYTU)

Columns: Metric · IRWD · AYTU
1. Valuation Multiples AYTU
Forward P/E 12.3x 9.2x
Trailing P/E 5.4x 9.2x
PEG Ratio N/M N/M
EV / Revenue 2.6x 0.3x
2. Growth & Scale IRWD
Revenue Growth (YoY) +9.0% +6.4%
Earnings Growth (YoY) +57.0% +0.0%
TTM Revenue (USD) $400M $58M
Market Cap $802.9M $19.6M
3. Profitability & Quality IRWD
Gross Margin 76.4% 64.0%
Operating Margin 62.9% -14.4%
Net Profit Margin 37.4% -24.8%
Return on Equity (ROE) -574.7% -52.5%
4. Balance Sheet & Cash Flow IRWD
Cash Generation (TTM) $205M -$1.4M
Cash Flow Margin 51.3% -2.4%
Net Cash / Leverage $250M Net Debt $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IRWD
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 63.1% (6th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat AYTU
OpEx & R&D Intensity 13.5% of Rev ($54M) 78.4% of Rev ($45M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IRWD (6) vs AYTU (4)
Institutional Metric IRWD AYTU Criterion Row Edge
Market Capitalization
Scale
$802.9M $19.6M Larger Scale IRWD
Trailing P/E Ratio
Valuation
5.4x 9.2x Lower Multiple IRWD
Forward P/E Ratio
Valuation
12.3x 9.2x Lower Multiple AYTU
Revenue Growth (YoY)
Growth
+9.0% +6.4% Higher Growth IRWD
Operating Margin (TTM)
Profitability
62.9% -14.4% Higher Margin IRWD
Net Profit Margin
Profitability
37.4% -24.8% Higher Margin IRWD
Return on Equity (ROE)
Capital Efficiency
-574.7% -52.5% Higher ROE AYTU
52-Week Range Position
Momentum
68% ($3–$6) 5% ($2–$3) Stronger Trend IRWD
Beta / 30D Volatility
Risk Regime
1.37β · 54% Vol 0.65β · 35% Vol Lower Realized Risk AYTU
Unified Institutional Score
Composite Signal
34.8 / 100 (SELL) 48.9 / 100 (HOLD) Higher Composite AYTU
Trailing 12M Revenue (USD)
Operating Scale
$400M $58M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
76.4% 64.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.6x EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$205M ($250M Net Debt) -$1.4M ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IRWD +50.13 pp
IRWD: +38.86% · AYTU: -11.27%
3M Horizon IRWD +36.07 pp
IRWD: +12.76% · AYTU: -23.31%
6M Horizon IRWD +52.67 pp
IRWD: +38.86% · AYTU: -13.81%
1Y Horizon IRWD +56.35 pp
IRWD: +44.21% · AYTU: -12.14%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IRWD Revenue AYTU Revenue IRWD Op. Margin AYTU Op. Margin Margin Leader
FY2019 $430M $10M 28.0% -230.1% IRWD
FY2020 $390M $30M 36.7% -76.5% IRWD
FY2021 $410M $70M 56.1% -89.7% IRWD
FY2022 $410M $100M 61.0% -113.7% IRWD
FY2023 $440M $110M -213.5% -15.9% AYTU
FY2024 $350M $70M 26.5% -2.4% IRWD
FY2025 $300M $70M 33.3% -11.8% IRWD
FY2026 N/A $60M N/A -14.4% AYTU

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IRWD CONSOLIDATION
134d in phase · OBV ACCUMULATION
Current IV 63.1%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact IRWD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AYTU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AYTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IRWD Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $802.9M market capitalization and 62.9% operating margin.
OpEx & R&D Reinvestment 13.5% of Rev ($54M)
90D Engineering Disclosures 0 Published
AYTU Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $19.6M market capitalization and -14.4% operating margin.
OpEx & R&D Reinvestment 78.4% of Rev ($45M)
90D Engineering Disclosures 0 Published

Investor FAQ IRWD vs AYTU Key Questions & Quantitative Answers

As of Nov 16, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is the stronger overall head-to-head candidate over AYTU BioPharma, Inc. (AYTU) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). IRWD carries a Unified Composite Score of 34.8/100 (SELL) at $4.86 (12.3x Forward P/E, 62.9% operating margin), whereas AYTU carries 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin). Composite vs. Pillar Nuance: While AYTU currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. IRWD 34.8/100 SELL), IRWD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (62.9% vs. -14.4% operating margin) and revenue trajectory (+9.0% vs. +6.4% YoY). Technical & Structure Timing Caution: IRWD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 75.5); meanwhile AYTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IRWD leads the Growth & Scale pillar: IRWD posts +9.0% YoY revenue growth and +57.0% YoY earnings growth on $400M TTM revenue (76.4% gross margin, 62.9% operating margin), compared with AYTU at +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), IRWD cumulative revenue shifted -30.2% while AYTU shifted +500.0%. In operating R&D and SG&A reinvestment, IRWD deploys 13.5% of Rev ($54M) (0 90-day corporate R&D disclosures) versus 78.4% of Rev ($45M) (0 disclosures) for AYTU.

AYTU screens cheaper on headline valuation multiples. IRWD trades at 12.3x Forward P/E, 5.4x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (51.3% FCF margin), whereas AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IRWD (-574.7% ROE) versus AYTU (-52.5% ROE) capital efficiency.

In options market volatility and institutional positioning, IRWD carries 63.1% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.37β · 54% Vol realized risk). By comparison, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.